Troponin leak in heart failure: Moving forward to arrest cardiomyocyte attrition and promote myocardial regeneration

International Journal of Cardiology

Volumn 162, Issue 3, 2013, Pages 137-139

  Tan, Lip Bun ^a   Hothi, Sandeep S ^b   Tan, David K H ^c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Biomarkers; Cardiomyocyte injury; Heart failure; Myocardial regeneration; Progressive cardiac dysfunction; Troponins

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TROPONIN; TROPONIN I;

CARDIOVASCULAR RISK; CELL CYCLE ARREST; CELL DEATH; CELL TRANSPLANTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; EDITORIAL; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; MEDICAL RESEARCH; MUSCLE REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; PROTEIN SYNTHESIS; RISK FACTOR; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CELL DAMAGE; CELL REGENERATION; DISEASE MARKER; HEART MUSCLE NECROSIS; MORTALITY; PROTEIN BLOOD LEVEL; SURVIVAL PREDICTION;

HEART FAILURE; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; REGENERATION; TROPONIN;

EID: 84872492233     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.01.090     Document Type: Editorial

References (61)

1. S.G. Williams, D. Barker, D.F. Goldspink, and L.B. Tan A reappraisal of concepts in heart failure: central role of cardiac power reserve Arch Med Sci 1 2005 65 74
2. Ather, S., Hira, R.S., Shenoy, M., et al. Persistent Low-Level Troponin I Elevation is a Worse Prognostic Indicator than Occasional Injury Pattern in Patients Hospitalized with Heart Failure. International Journal of Cardiology (In Press), http://dx.doi.org/10.1016/j.ijcard.2011.10.113.
3. E. Giannitsis, H. Steen, and K. Kurz Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T J Am Coll Cardiol 51 3 2008 Jan 22 307 314
4. A.K. Hassan, S.C. Bergheanu, and H. Hasan-Ali Usefulness of peak troponin-T to predict infarct size and long-term outcome in patients with first acute myocardial infarction after primary percutaneous coronary intervention Am J Cardiol 103 6 2009 Mar 15 779 784
5. L.K. Newby, R.H. Christenson, and E.M. Ohman Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators Circulation 98 18 1998 1853 1859 3
6. E. Braunwald, J. Ross Jr., and E.H. Sonnenblick Mechanisms of contraction of the normal and failing heart N Engl J Med 277 1967 794 800 853-63, 910-20, 962-71, 1012-22
7. E.H. Sonnenblick Implications of muscle mechanics in the heart Fed Proc 21 1962 975 990
8. E.H. Sonnenblick Force-velocity relations in mammalian heart muscle Am J Physiol 202 1962 931 939
9. H. Suga Theoretical analysis of a left ventricular pumping model based on the svstolic time varying pressure-volume ratio IEEE Trans BioMed Eng 18 1971 47 55
10. M. Packer, J.R. Carver, and R.J. Rodeheffer Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group N Engl J Med 325 21 1991 Nov 21 1468 1475
11. B.F. Uretsky, M. Jessup, and M.A. Konstam Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group Circulation 82 3 1990 Sep 774 780
12. J.N. Cohn, S.O. Goldstein, and B.H. Greenberg A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators N Engl J Med 339 25 1998 Dec 17 1810 1816
13. W. Withering An Account of the Foxglove and Some of Its Medical Uses: with Practical Remarks on the Dropsy, and Some Other Diseases 1785 Swinney Birmingham
14. I.J. Benjamin, J.E. Jalil, L.B. Tan, K. Cho, K.T. Weber, and W.A. Clark Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis Circ Res 65 1989 657 670
15. Y. Tonomura, Y. Mori, M. Torii, and T. Uehara Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats Toxicology 266 1-3 2009 Dec 21 48 54
16. L.B. Tan, J.G. Burniston, W.A. Clark, Y.L. Ng, and D.F. Goldspink Characterisation of adrenoceptor involvement in skeletal and cardiac myotoxicity induced by sympathomimetic agents J Cardiovasc Pharmacol 41 2003 518 525
17. M. Packer, A.J. Coats, and M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 22 2001 May 31 1651 1658
18. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 9146 1999 Jan 2 9 13
19. A. Hjalmarson, S. Goldstein, and B. Fagerberg Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group JAMA 283 10 2000 Mar 8 1295 1302
20. M.D. Flather, M.C. Shibata, and A.J. Coats SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 3 2005 Feb 215 225
21. K. Swedberg Exercise testing in heart failure. A critical review Drugs 47 Suppl 4 1994 14 24
22. M.A. Pfeffer, E. Braunwald, and L.A. Moye Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement (SAVE) trial N Engl J Med 327 1992 669 677
23. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
24. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on mortality and morbidity in patients with severe heart failure N Engl J Med 341 1999 709 717
25. Beta-Blocker Evaluation of Survival Trial Investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 22 2001 May 31 1659 1667
26. J.N. Cohn, M.A. Pfeffer, and J. Rouleau MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) Eur J Heart Fail 5 5 2003 Oct 659 667
27. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, C. Orlandi Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 12 2007 Mar 28 1319 1331
28. C.M. O'Connor, M. Fiuzat, and K. Swedberg Influence of global region on outcomes in heart failure beta-blocker trials J Am Coll Cardiol 58 9 2011 Aug 23 915 922
29. P. Carson, S. Ziesche, G. Johnson, and J.N. Cohn Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group J Card Fail 5 3 1999 178 187
30. C.M. O'Connor, R.C. Starling, and A.F. Hernandez Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 1 2011 Jul 7 32 43
31. B. Levine, J. Kalman, L. Mayer, H.M. Fillit, and M. Packer Elevated circulating levels of tumor necrosis factor in severe chronic heart failure N Engl J Med 323 4 1990 Jul 26 236 241
32. D.L. Mann, J.J. McMurray, and M. Packer Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 13 2004 Apr 6 1594 1602
33. K.K. Witte, and A.L. Clark Why does chronic heart failure cause breathlessness and fatigue? Prog Cardiovasc Dis 49 5 2007 Mar-Apr 366 384
34. D. Schlosshan, D. Barker, C. Pepper, G. Williams, C. Morley, and L.B. Tan CRT improves the exercise capacity and functional reserve of the failing heart through enhancing the cardiac flow- and pressure-generating capacity Eur J Heart Fail 8 5 2006 Aug 515 521
35. D. Schlosshan, D. Barker, N. Lewis, C. Pepper, and L.B. Tan A mechanistic investigation into how long-term resynchronization therapy confers ongoing cardiac functional benefits and improved exercise capacity Am J Cardiol 103 5 2009 Mar 1 701 708
36. J.L. Hall, D.R. Fermin, and E.J. Birks Clinical, molecular, and genomic changes in response to a left ventricular assist device J Am Coll Cardiol 57 6 2011 Feb 8 641 652
37. J.N. Cohn, D.G. Archibald, and S. Ziesche Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study N Engl J Med 314 24 1986 Jun 12 1547 1552
38. S. Ziesche, F.R. Cobb, J.N. Cohn, G. Johnson, and F. Tristani Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group Circulation 87 6 Suppl 1993 Jun VI56 VI64
39. E. Missov, C. Calzolari, and B. Pau Circulating cardiac troponin I in severe congestive heart failure Circulation 96 9 1997 Nov 4 2953 2958
40. L. La Vecchia, G. Mezzena, and R. Ometto Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin Am J Cardiol 80 1 1997 Jul 1 88 90
41. S.M. Macin, E.R. Perna, and J.P. Cimbaro Canella Increased levels of cardiac troponin-T in outpatients with heart failure and preserved systolic function are related to adverse clinical findings and outcome Coron Artery Dis 17 8 2006 Dec 685 691
42. W.L. Miller, K.A. Hartman, M.F. Burritt, D.E. Grill, and A.S. Jaffe Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure J Am Coll Cardiol 54 18 2009 Oct 27 1715 1721
43. S. Masson, R. Latini, and I.S. Anand An update on cardiac troponins as circulating biomarkers in heart failure Curr Heart Fail Rep 7 1 2010 Mar 15 21
44. R.D. Kociol, P.S. Pang, M. Gheorghiade, G.C. Fonarow, C.M. O'Connor, and G.M. Felker Troponin elevation in heart failure prevalence, mechanisms, and clinical implications J Am Coll Cardiol 56 14 2010 Sep 28 1071 1078
45. M. Nishikai, and M. Reichlin Purification and characterization of a nuclear non-histone basic protein (Mi-1) which reacts with anti-immunoglobulin sera and the sera of patients with dermatomyositis Mol Immunol 17 9 1980 Sep 1129 1141
46. J.F. Glatz, A.H. Kleine, F.A. van Nieuwenhoven, W.T. Hermens, M.P. van Dieijen-Visser, and G.J. van der Vusse Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans Br Heart J 71 2 1994 Feb 135 140
47. A.R. Marks, J.O. McIntyre, T.M. Duncan, H. Erdjument-Bromage, P. Tempst, and S. Fleischer Molecular cloning and characterization of (R)-3-hydroxybutyrate dehydrogenase from human heart J Biol Chem 267 22 1992 Aug 5 15459 15463
48. T.D. Wood, L.H. Chen, C.B. White, P.C. Babbitt, G.L. Kenyon, and F.W. McLafferty Sequence verification of human creatine kinase (43 kDa) isozymes by high-resolution tandem mass spectrometry Proc Natl Acad Sci U S A 92 25 1995 Dec 5 11451 11455
49. S.Y. Jeong, K.J. Kim, D.J. Kim, S.W. Oh, and E.Y. Choi Sandwich ELISA for measurement of cytosolic aspartate aminotransferase in sera from patients with liver diseases Clin Chem 49 5 2003 May 826 829
50. K.A. Reimer, and R.B. Jennings Myocardial ischemia, hypoxia and infarction H.A. Fozzard, E. Haber, R.B. Jennings, A.M. Katz, H.E. Morgan, The Heart and Cardiovascular System. Scientific Foundations 1986 Raven Press New York 1133 1201
51. L.B. Tan, I.J. Benjamin, and W.A. Clark β-Adrenergic receptor desensitisation may serve a cardioprotective role Cardiovasc Res 26 6 1992 Jun 608 614
52. I.J. Benjamin, J.E. Jalil, L.B. Tan, K. Cho, K.T. Weber, and W.A. Clark Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis Circ Res 65 3 1989 Sep 657 670
53. D.F. Goldspink, J.G. Burniston, G.M. Ellison, W.A. Clark, and L.B. Tan Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp Physiol 89 4 2004 Jul 407 416
54. L.B. Tan, J.E. Jalil, R. Pick, J.S. Janicki, and K.T. Weber Cardiac myocyte necrosis induced by angiotensin II Circ Res 69 5 1991 Nov 1185 1195
55. J.G. Burniston, G.M. Ellison, W.A. Clark, D.F. Goldspink, and L.B. Tan Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others Cardiovasc Toxicol 5 4 2005 355 364
56. D.F. Goldspink, J.G. Burniston, and L.B. Tan Cardiomyocyte death and the ageing and failing heart Exp Physiol 88 3 2003 May 447 458
57. L.B. Tan, and R. Murphy Shifts in mortality curves: saving or extending lives? Lancet 354 9187 1999 Oct 16 1378 1381
58. G.M. Ellison, D. Torella, and S. Dellegrottaglie Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart J Am Coll Cardiol 58 9 2011 Aug 23 977 986
59. M.A. Laflamme, and C.E. Murry Heart regeneration Nature 473 7347 2011 May 19 326 335
60. S.G. Williams, L.L. Ng, and R. O'Brien Complementary roles of simple variables, NYHA and N-BNP, in indicating aerobic capacity and severity of heart failure Int J Cardiol 102 2 2005 Jul 10 279 286
61. C. Enoki, H. Otani, D. Sato, T. Okada, R. Hattori, and H. Imamura Enhanced mesenchymal cell engraftment by IGF-1 improves left ventricular function in rats undergoing myocardial infarction Int J Cardiol 138 1 2010 Jan 7 9 18